期刊文献+

国产雷帕霉素洗脱支架远期预后的临床研究 被引量:4

Clinical study on major adverse cardiac events(MACE) rate in patients implanted with rapamycin-eluting stents
在线阅读 下载PDF
导出
摘要 目的观察冠心病患者应用国产雷帕霉素洗脱支架后临床不良心血管事件(major adverse cardia cevent,MACE)包括心源性死亡、再发非致死性心肌梗死、再次血运重建的发生率。方法2003年11月至2006年12月,共入选267例患者,国产雷帕霉素(Firebird,上海微创公司)支架组145例,进口雷帕霉素(Cypher,美国强生公司)支架组122例。术后严格要求患者服用阿司匹林和噻氯匹定或氯吡格雷至少12个月。通过门诊或电话随访术后患者MACE的发生率,部分患者进行了冠状动脉造影复查。结果随访(31±11)个月,失访患者9例(Firebird组6例、Cypher组3例),失访率3.37%。随访期间总的MACE的发生率在Firebird组10.79%、Cypher组11.76%,两组无显著性差异(P=0.95),两组冠状动脉介入治疗(PCI)术后<1年及>1年MACE分别为5.04%、7.02%和5.04%、8.08%,P<0.05;Firebird支架和Cypher支架的血栓发生率分别为1.44%、1.68%,P>0.05。两组冠状动脉造影再狭窄率分别为17.6%(6/34)、19%(8/42),无显著性差异。结论远期临床随访结果表明,国产Firebird支架与Cypher支架临床心血管事件、支架内血栓的发生率均较低,两组无显著性差异,两者的安全性与有效性相似。延长联合抗血小板治疗时间很有必要。 Objective To observe the major adverse cardiac events (MACE including cardiac death, non - fatal myocardial infarction or target vessel revascularization) rate in patients implanted with rapamycin - eluting stents (Firebird). Method From November 2003 to December 2006, a total of 267 consecutive patients with coronary artery disease were randomized to Firebird (n = 145, Firebird group) and Cypher( n = 122, Cypher group) stent treatment. Fully antiplatelet therapy was performed for 12 months after percutaneous coronary intervention. Follow - up was done by telephone or interview at clinic. A small proportion of patients was followed up by angiography. Results 258 patients were followed up for (31±11 ) months, with 9 patients(3.37 % ) lost to follow - up, including 6 in Firebird stents group and 3 in Cypher stents group. MACE was 10.79% , 11.76% in Firebird and Cypher group, respectively. There was no difference of MACE between the two groups( P = 0.95). There were no difference with restenosis after PCI between the two groups, which were 17.6 % (6/34) and 19 % (8/42) in Firebird and Cypher groups, respectively. Conclusion There were a lower MACE incident rate in Firebird group and Cypher stenting group, and no statistical difference between the two groups. Firebird stent is an alternative one for PCI wit the same efficacy and safety . It is important that standard antiplatelet therapy shoule be prolnged.
出处 《浙江临床医学》 2008年第6期746-747,共2页 Zhejiang Clinical Medical Journal
关键词 药物洗脱支架 临床心血管事件 支架内血栓 Drug- eluting stent Clinical major adverse cardiac events Stent thrornbosisd3osis
  • 相关文献

参考文献10

  • 1Shafiq N , Malhotra S, Pandhl P, et al. A meta - analysis of clinical trials of paclitaxel and sirolimus - eluting stents in patients with obstructive coronary artery disease. Br J Clin Pharmacol,2005,59( 1 ):94 - 101.
  • 2Morice MC, Colombo A, Meier B, et al. Sirolimus vs paclitaxel - during stents in de novo coronary artery lesions. The REALITY trial: a randomized controlled trial. JAMA, 2006,295 (8) : 895 - 904.
  • 3Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug - eluting stents. JAMA, 2005,293(17) :2126 - 2130.
  • 4Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus - eluting and paclitaxel-eluting coronary stents. N Engl J Med, 2007,356 (10) :998 - 1008.
  • 5Shen W, Zhang R, Shen Y, et al. Optimal timing for coronary in unstable angina patients. Chin Med J,2001,114( 1 ) : 59 - 61.
  • 6Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 2007,115 : 234 - 2351.
  • 7何继强,李峥,高阅春,吴长燕,张晓玲,李宇,赵华,汪烨,韩智红,张维东,陈方.国产西罗莫司洗脱支架治疗冠心病的近远期疗效[J].中华心血管病杂志,2007,35(3):216-219. 被引量:5
  • 8Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilizalion of sirolimus- during stents comared with conventional bare stent implantation in the "real world": the Rapamycin- Eluting Stent Evaluated At Rotterdam Cardiology Hospital(RESEARCH) registry. Circulation,2004,109(2):190-195.
  • 9Ong ATL,Van Domburg RT, Aoki J, et al. Sirolimus- during stents remain superior to bare - metal stents at two yeats: Medium - term results from the Rapamycin- Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol,2006,47(7):1356- 1360.
  • 10Moses JW, Leon MB, Pomma JJ, et al. Sirolimus - eluting stents versus standard stents in Patients with stenosis in a native coronary artery. N Engl J Med,2003,349(14) : 1315 - 1323.

二级参考文献8

  • 1调查协作组,霍勇.中国多中心药物洗脱支架急性或亚急性血栓的调查[J].中国介入心脏病学杂志,2005,13(3):131-134. 被引量:24
  • 2Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003, 349(14) : 1315-1323.
  • 3Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engt J Med,2002, 346(23) : 1773-1780.
  • 4Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation, 1999,99 ( 16 ) :2164-2170.
  • 5Chen D, Krasinski K,Sylvester A, et al. Downregulation of cyclindependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27 (KIP1), an inhibitor of neointima formation in the rat carotid artery. J Clin Invest, 1997,99(10) :2334-2341.
  • 6Marx SO,Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res,1995,76(3) :412-417.
  • 7Lemos PA, Serruys PW, van Domburg RT, et al . Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation, 2004.109(2) : 190-195.
  • 8Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent:should we be cautious? Circulation, 2004, 109(6) :701-705.

共引文献4

同被引文献54

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部